Kailera Therapeutics, Inc. (KLRA) stock
KLRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026
$11.58−0.21 (-1.78%)
Close on Nov 19, 2026Market cap $1.50BP/E –Yield –
Kailera Therapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$95.67M | – |
| Q2 FY2026 | Jun 30, 2026 | -$111.31M | – |
| Q1 FY2026 | Mar 31, 2026 | -$78.87M | – |
| Q3 FY2025 | Sep 30, 2025 | -$39.62M | – |
| Q2 FY2025 | Jun 30, 2025 | -$28.95M | – |
| Q1 FY2025 | Mar 31, 2025 | -$17.98M | – |
See a number that looks wrong?